Friday, 19 December 2014
Last updated 13 hours ago
Jan 27 2014 | 11:38am ET
Elliott Management will ensure the success of a pharmaceutical merger, after all.
The hedge fund, which ended its battle with McKesson Corp. when the company boosted its offer for Celesio by 2%, has agreed to sell its roughly 25% stake in Celesio to Franz Haniel & Cie, which already owns a majority stake in the company. In turn, Haniel has accepted McKesson's offer, which the latter had dropped two weeks ago after it failed to win the necessary 75% backing from shareholders.
In addition, Elliott has agreed to sell its convertible bonds in Celesio to McKesson at an undisclosed price, and to stop interfering with the transaction, Reuters reports. Elliott reportedly made most of its profit on the deal through the sale of the convertible bonds.
The deals will allow McKesson to take control of Celesio through a domination and profit-and-loss transfer agreement, one that will eventually force Celesio's minority shareholders to give up their stock.
"We are excited to move forward with our acquisition of Celesio," McKesson CEO John Hammergren said.
Dec 1 2014 | 10:21am ET
As 2014 winds down, Northern Trust Hedge Fund Services executives took some time to share their outlook on trends facing the industry in 2015. Read more…
Jeff Sprecher was simply looking for a platform to trade energies when launching ICE 14 years ago but it has grown to reach the pinnacle of both the listed futures and equities world.